Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

In The Spotlight

US State Regulatory Spotlight on Healthcare Transactions: Reflections From 2024

Shiny transparent capsule filled with colorful spheres

November 26, 2024 Podcast

Episode 87 — Drug Pricing: What’s in the New CMS Medicaid Final Rule?

Close up of Asian women with hi tech digital technology screen over the eye.

May 30, 2024 Webcast

US Regulators’ Joint Inquiry Into Healthcare Consolidation: Navigating the New Landscape

April 30, 2024 Client Alert

US Regulators Announce Inquiry Into Healthcare Consolidation

April 11, 2024 Resource

Healthcare & Life Sciences Market Update

November 26, 2024 Podcast

Episode 87 — Drug Pricing: What’s in the New CMS Medicaid Final Rule?

CMS sought far-reaching changes to the Medicaid Drug Rebate Program in its 2023 proposed rule implementing the Medicaid Services Investment and Accountability Act. Find out which proposals CMS dropped from the final rule, and which changes became effective November 19, 2024.

The White House South Portico from the ground up.

November 21, 2024 Webcast

A Look Ahead: The Trump Administration’s Regulatory and Enforcement Priorities

Latham lawyers discuss trends and potential initiatives to expect. MCLE credits offered.

November 14, 2024 Webcast

Patents and Trade Secrets in Life Sciences: What to Know About Protecting Your IP Innovations

October 30, 2024 Webcast

FDA Life Sciences Enforcement Update: Recent Trends and a Look Ahead

October 21, 2024 Podcast

Episode 86 — Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit

Episode 87 Drug Pricing What In the New CMS Medicaid Final Rule

November 26, 2024

Episode 87 — Drug Pricing: What’s in the New CMS Medicaid Final Rule?

October 21, 2024

Episode 86 — Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit

One of the year’s major drug pricing conferences just concluded in Chicago. Join the Latham team to discuss takeaways from the conference, including highlights from remarks by government speakers.

September 19, 2024

The Demise of Chevron Deference and Its Impact on the Healthcare and Life Sciences Industries

Latham lawyers discuss the implications of the US Supreme Court decision in Loper Bright. MCLE credit offered.

Episode 85 Drug Pricing How Demise Chevron Deference and Other Litigation May Impact Pharma Industry

September 19, 2024

Episode 85 — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Recent Supreme Court decisions, such as those overruling Chevron deference, as well as ongoing manufacturer challenges to the Inflation Reduction Act and state 340B laws, will likely have a significant impact on the pharmaceutical industry.

August 19, 2024

Episode 83 — Drug Pricing: How Are Payers Responding to the IRA?

Explore how health insurance companies are adapting to the Inflation Reduction Act's new requirements, including the Part D redesign.

June 21, 2024

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.

June 13, 2024

Episode 81 — Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

The new ASP reporting website highlights the increasing significance of data collection portals — and yet the number of permitted users is very small. Join us as we learn from leading practitioners at Riparian how to navigate the complex web of compliance requirements.

May 30, 2024

US Regulators’ Joint Inquiry Into Healthcare Consolidation: Navigating the New Landscape

Latham’s healthcare enforcement and antitrust practitioners discuss how companies can navigate the complexities of healthcare consolidation and regulatory compliance. MCLE credit offered.

March 06, 2024

Next Generation of Nicotine: Center for Tobacco Products — 2024 Outlook

Latham’s FDA Regulatory lawyers discuss CTP’s 2024 agenda for tobacco and nicotine products. MCLE credit offered.

February 21, 2024

2024 FDA Outlook: Healthcare & Life Sciences

Latham’s Healthcare & Life Sciences lawyers discuss FDA’s regulatory and legislative agenda for 2024. MCLE credit offered.

Our Archive

December 2, 2024 Our Work

Latham & Watkins Advises Grünenthal on €500 Million Bond

Capital markets team represents leading pharmaceutical company on significant issuance.

November 25, 2024 Our Work

Latham Advises Novo Holdings on Acquisition of Benchmark Genetics

London team advises on transaction to acquire a leader in aquaculture genetics.

November 22, 2024 Our Work

Latham & Watkins Advises on Verrica Pharmaceuticals Inc.’s Public Offering

November 22, 2024 Our Work

Latham & Watkins Advises Carlyle on Secondary Offering of QuidelOrtho Corporation Common Stock

November 21, 2024 Our Work

Latham & Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering

Blurry vision of the sun reflected in the glass skyscraper.

November 26, 2024 Recognition

Latham Named Debtor-Side Law Firm of the Year by Global Restructuring Review

Firm earns top recognition for handling complex and precedent-setting restructurings in multiple global jurisdictions.

Abstract blue light and shade triangle shape creative background illustration.

November 8, 2024 Recognition

Litigators of the Week Runners-Up and Shout Outs — Avadel Pharmaceuticals and The Trade Desk

Latham lawyers were honored for securing big victories for Avadel Pharmaceuticals and The Trade Desk.

October 23, 2024 Recognition

MVP: Mandy Reeves

Managing Partner of Latham’s Washington, D.C. office and former Global Co-Chair of the firm’s Antitrust & Competition Practice, Mandy Reeves earned MVP recognition from Law360 for her stellar year leading blockbuster merger clearances, antitrust trial teams, and complex anticompetitive conduct investigations for her clients.